Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pasithea Therapeutics Corp (KTTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: KTTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.68% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.23M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta 0.26 | 52 Weeks Range 0.65 - 7.50 | Updated Date 08/15/2025 |
52 Weeks Range 0.65 - 7.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -46.84% | Return on Equity (TTM) -82.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6745757 | Price to Sales(TTM) 42.15 |
Enterprise Value -6745757 | Price to Sales(TTM) 42.15 | ||
Enterprise Value to Revenue 277.44 | Enterprise Value to EBITDA 2.9 | Shares Outstanding 7443580 | Shares Floating 6931236 |
Shares Outstanding 7443580 | Shares Floating 6931236 | ||
Percent Insiders 3.26 | Percent Institutions 15.06 |
Upturn AI SWOT
Pasithea Therapeutics Corp
Company Overview
History and Background
Pasithea Therapeutics Corp. was founded in 2019 and is a biotechnology company focused on the discovery, research, and development of new and effective treatments for central nervous system (CNS) disorders. They are concentrating efforts on new chemical entities and genetic therapies. They have acquired several companies, including Pasithea Pharmaceuticals.
Core Business Areas
- CNS Therapeutics: Development of novel therapies for central nervous system disorders, including depression, anxiety, and neurodegenerative diseases.
- Genetic Therapies: Focuses on gene therapy approaches for CNS disorders, aiming for more precise and long-lasting treatments.
- New Chemical Entity Research: Discovery and development of novel compounds targeting CNS pathways.
Leadership and Structure
The leadership team includes key executives with expertise in drug development and business strategy. The organizational structure likely follows a functional model with departments for research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Pasithea Pharmaceuticals: Acquired company with existing preclinical and clinical programs. Market share data is difficult to assess until drug products are approved. Competitors include pharmaceutical companies focusing on CNS disorders.
- Preclinical CNS Programs: Early-stage drug candidates targeting various CNS disorders. Competitors are other biotech and pharmaceutical companies with similar pipelines.
Market Dynamics
Industry Overview
The CNS therapeutics market is large and growing, driven by increasing prevalence of mental health disorders and aging populations. The market is competitive with a mix of established pharmaceutical companies and emerging biotech firms.
Positioning
Pasithea Therapeutics Corp. is positioned as a smaller biotech company focused on innovative therapies for CNS disorders. Their competitive advantage relies on novel drug candidates and gene therapy approaches.
Total Addressable Market (TAM)
The TAM for CNS therapeutics is estimated to be hundreds of billions of dollars. Pasithea's position is early-stage, focusing on specific niches within this large market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches (gene therapy, new chemical entities)
- Experienced leadership team
- Strong focus on CNS disorders
- Acquired company with existing programs
Weaknesses
- Early-stage development programs
- Limited financial resources compared to larger pharmaceutical companies
- High risk of clinical trial failure
- Small market capitalization
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new CNS indications
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- ALNY
Competitive Landscape
Pasithea Therapeutics Corp. faces intense competition from larger pharmaceutical companies with greater resources and established market presence. Their success depends on the differentiation and efficacy of their novel therapies.
Major Acquisitions
Pasithea Pharmaceuticals
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: Expanded pipeline and added new therapeutic programs targeting CNS disorders.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and acquisitions.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing preclinical programs, conducting clinical trials and raising capital.
Summary
Pasithea Therapeutics Corp. is an early-stage biotech company with a promising pipeline of CNS therapeutics. Its focus on novel approaches like gene therapy is a strength, but it faces significant risks associated with clinical development and competition from larger companies. They need to carefully manage cash flow and secure partnerships to advance their programs. The overall success hinges on positive clinical trial outcomes and regulatory approvals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Third-party analyst reports (estimates only)
- Industry databases
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pasithea Therapeutics Corp
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-09-15 | CEO & Director Dr. Tiago Reis Marques M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.pasithea.com |
Full time employees 4 | Website https://www.pasithea.com | ||
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.